Peer-Reviewed Articles
Agur Z, Kirnasovsky O, Levi L. Normal and pathological renewal of damaged tissues by stem cell homing analyzed in a simple discrete model. (submitted)
Kirnasovsky O.U., Kogan Y, Agur Z. Analysis of a mathematical model for the molecular mechanism of mammary stem cell fate decision. Mathematical Modelling of Natural Phenomena 2008 3(7) pp. 78-89 [PDF]
Kirnasovsky O.U., Kogan Y, Agur Z. Resilience in Stem Cell renewal: Development of the Agur – Daniel – Ginossar Model. Disc. Cont. Dyn. Systems (in press) [PDF]
Yuri Kogan, Benjamin Ribba, Nitsan Dahan, Karen Marron, Vladimir Vainstein, Zvia Agur. Intensifed Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement. Mathematical Modelling of Natural Phenomena 2007 2(3), pp. 47-68 [PDF]
Natalie Kronik, Yuri Kogan, Vladimir Vainstein, Zvia Agur. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother 2007 Mar;57(3):425-439 (2008). Epub 2007 Sep 7. [PDF]
Cappuccio A, Elishmereni M, and Agur Z. Optimization of Interleukin-21 Immunotherapeutic Strategies. Jour Theor. Biol 2007 248 (2) pp. 259-66. [PDF]
Kheifetz Y, Elishmereni M, Horowitz S and Agur Z. Fluid retention side-effects of the chemotherapy-supportive treatment interleukin11: Mathematical modelling as affected by data availability. GTHM Computational and Mathematical Methods in Medicine. 7 (2-3) 2006 pp. 71-84. [PDF]
Vainstein V., Ginosar Y., Shoham M., Ianovski A., Rabinovich A., Kogan Y., Selitser V., Agur Z. Improving cancer therapy by Doxorubicin and Granulocyte colony-stimulating factor: Insights from a Computerized Model of Human Granulopoiesis. Mathematical Modelling of Natural Phenomena 2006 1(2), pp.70-80. [PDF]
Agur Z., Hassin R., Levy S. Optimizing chemotherapy scheduling using local search heuristics. Operations Research 2006; 54 (5): 829-846. [PDF]
Cappuccio A., Elishmereni M., Agur Z. Cancer immunotherapy by interleukin-21 treatment strategies evaluated in a amathematical model. Can. Res. 2006; 66 (14): 7293-300. [PDF]
Agur Z., Biomathematics in the development of personalized medicine in oncology. Future Oncol. 2006; 2 (1): 39-42. [PDF]
Forys U., Kheifetz Y., Kogan Y. Critical-point analysis for three-variable cancer angiogenesis modeling. Mathematical Biosciences and Engineering. 2005; 2 (3): 511-525. [PDF]
Kheifetz Y., KoganY. & Agur Z. Long-range predictability in models of cell populations subjected to phase-specific drugs: Growth-rate approximation using properties of positive compact operators. Mathematical Models & Methods in the Applied Sciences. 2006; 16 (7), 1-18. [PDF]
Presnov E.V. & Agur Z . The role of time-delays, slow processes and chaos in modulating the cell cycle clock . Mathematical Biosc & Engi. 2005; 2 (3): 625-542. [PDF]
Vainstein V., Ginosar Y., Shoham M., Ranmar D., Ianovski A., Agur Z. The complex effect of granulocyte on human granulopoiesis analyzed by a new physiologically-based mathematical model. Jour Theor Biol. 2005; 234 (3); 311-27. [PDF]
Ribba B., Marron K., Alarcon T., Maini P, Agur Z. A mathematical model of doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results Bull.Math. Biol. 2005; 67, 79-99. [PDF]
Arakelyan L., Merbl Y., Agur Z. Vessel maturation effects on tumor growth: computer model validated in implanted human ovarian carcinoma spheroids. Eur. Jour. Cancer. 2005; 41: 159-167. [PDF]
Kheifetz Y., Kogan Y., Agur Z. Matrix and compact operator description of resonance and antiresonance in cell populations subjected to phase specific drugs. Jour. Medical Informatics & Technologies. 2004; 8, MM-11 – MM-29. [PDF]
Agur Z., Arakelyan L. Daugulis P., Ginosar Y. Hopf point analysis for angiogenesis models, Discrete and Continuous Dynamics - Series B, 2004, 4(1), pp.29-38. [PDF]
Skomorovski K., Harpak H., Ianovski A., Vardi M., Visser TP., Hartong S., Van Vliet H., Wagemaker G., Agur Z. New TPO treatment schedules of increased safety and efficacy: pre clinical validation of a thrombopoiesis simulation model. Br. Jour. Haematol, 123 (4), 2003 (pp. 683-691)., [PDF]
Arakelyan L, Vainstain V, and Agur Z. A computer algorithm describing angiogenesis and vessel maturation and its use for studying the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth, Angiogenesis 5(3), 2002 (pp.203-14). [PDF]
Agur Z, Daniel Y, and Ginosar Y. The universal properties of stem cells as pinpointed by a simple discrete model. Jour. Math. Biol2002; 44 (1): 79-86. [PDF]
Stone L. Shulgin B. and Agur Z. Theoretical Examination of the Pulse Vaccination Policy in the SIR Epidemic model. Jour. Math. Comp. Modelling, 31, 2000 (pp. 207-215).
Shochat, E. Hart, D & Agur, Z. Using Computer Simulations for Evaluating The Efficacy of Breast Cancer Chemotherapy Protocols Jour. Math. Models & Methods in Applied Sciences Vol. 9 (4) 1999 (pp. 599-615). Chapters in Books Zvia Agur, Moran Elishmereni, Yuri Kogan, Yuri Kheiffetz, Irit Ziv, Meir Shoham, and Vladimir Vainstein. Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study, Preclinical Development Handbook, Shayne Gad Ed., John Wiley and Sons, USA. 2008, pp 1229-1266. [PDF]
Zvia Agur, Keren Marron, Hanita Shai, Yehuda L. Danon. Preparing for a smallpox bioterrorist attack: pulse vaccination as an optimal strategy. In Risk Assessment and Risk Communication Strategies in Bioterrorism Preparedness, M.S. Green et al (eds)., Springer 2007, pp 219-229. [PDF]
Agur Z, Kheiffets Y. Resonance and Anti-Resonance: from mathematical theory to clinical cancer treatment design, in "Handbook of Cancer Models With Applications to Cancer Screening, Cancer Traetment and Risk Assessment" World Scientific, Singapore and River Edge, New Jersey, (to appear). [PDF]
Castiglione F, Selitser V, Agur Z. Analysing Hypersensitivity to Chemotherapy in a Cellular Automata Model of the Immune System. Ch. 12, in: "Cancer Modelling and Simulation", Luigi Preziosi ed., CRC Press, LLC, (UK), 2003. [PDF]
Arakelyan L. et al., Multi-Scale Analysis of Angiogenic Dynamics and Therapy, Ch. 7, in: "Cancer Modelling and Simulation", Luigi Preziosi ed., CRC Press, LLC, (UK), 2003. [PDF]
Abstracts
Moran Elishmereni, Yuri Kheifetz, Antonio Cappuccio, Ori Inbar, Henrik S?ndergaard, Peter Thygesen, Rune Viig Overgaard, Zvia Agur, IL-21 Immunotherapy in Solid Cancers: Therapeutic Insights from a Preclinically Validated Mathematical PK/PD Model. American Association for Cancer Research, AACR, Mar 16-19, 2008 Dead Sea, Jordan, pp 95-96. [PDF]
Fatima S.F. Aerts Kaya, Trudi T.P. Visser, Simone C.C. Hartong, Zvia Agur*, Gerard Wagemaker . Eficacy of recombinant human and rhesus Thrombopoietin stimulated blood transfusions in comparison to unstimulated whole blood or thrombocyte transfusions in a non-human primate model. European Hematology Association (EHA) 13th Congress, June 12-15, 2008, Copenhagen, Denmark. [PDF]
Zvia Agur, Irit Ziv, Revital Shochat, Michael Wick, Craig Webb, David Hankins, Levon Arakelyan and David Sidransky Using a Novel Computer Technology for Tailoring Targeted and Chemotherapeutic Drug Schedules to the Individual Patient. First American Association for Cancer Research (AACR) International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Sep 12-15, 2006. [PDF]
Vainstein V., Ginosar Y., Shoham M., Ianovski A., Rabinovich A., Kogan Y., Selitser V., Ariad S., Chan S., Agur Z. Clinical validation of a physiologically-based computer model of human granulopoiesis and its use for improving cancer therapy by Doxorubicin and Granulocyte colony-stimulating factor (G-CSF). 48th Annual Meeting of the American Society of Hematology, Orlando, Florida, 9-12 December 2006. [PDF]
Cappuccio A, Elishmereni M, Agur Z, Cancer Immunotherapy by Interleukin-21: Theoretical Evaluation
Ziv I., Arakelyan L., Shohat R., Wick M., Webb C., Hankins D. Sidransky D., Agur Z. Novel Virtual Patient technology for predicting response of breast cancer and mesenchymal chondrosarcoma patients to mono- and combination therapy by cytotoxic and targeted drugs. 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", Prague Czech republic, 7-10 November 2006. [PDF]
Mukherjee A., Chan S., Arakelyan L., Samuel A., Belianina E., Ellis I., Paish C., Dahan N., Agur Z. Virtual patient (VCP) for treatment personalization: Prediction accuracy in metastatic brest cancer (MBC) oatients. NCRI Cancer conference, 2006. Birmingham, U.K., 8-11 October 2006. [PDF]
Agur Z. , Ziv I. , Shohat R. , Wick M. , Webb C. , Hankins D. , Arkelyan L. , Sidransky D., Using a novel computer technology for tailoring and chemotherapeutic drug schedules to the individual patient. AACR conference on Molecular Diagnostics in Cancer Therapeutic Development. Chicago, Illinois, 12-15 September 2006. [PDF]
Arakelyan L., Merbl Y., Vainstein V., Agur Z. A new cancer drug regimen based on the interplay between tumor growth and angiogenesis – Predictions of a mathematical model. SIAM Conference on the Life Sciences . Raleigh, North Carolina, 31July – 4 August 2006. [PDF]
Ziv I., Arkelyan L., Shohat R., Wick M., Webb C., Hankins D. Sidransky D., Agur Z. Novel virtual patient technology for personalizing single-agent and combination therapies of chemotherapeutic and targeted drugs: Validation in xenografted biopsies of mesenchymal chondrosarcoma patient. 2nd Joint American-Israeli Conference (JAICC) on "Novel Therapeutic Approaches to Cancer," Jerusalem, Israel, 28-30 June 2006. [PDF]
Agur Z., The Resonance effect: From Mathematical theory to clinical application in cancer drug design. The American Institute of Mathematics (AIM), The Modeling of Cancer Progression and Immunotherapy. Palo Alto, California, 12-16 December, 2005. [PDF]
Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z. Using In Silico thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, EHO(2003). [PDF]
Arakelyan L, Vainstain V, and Agur Z. 2002. Optimizing anti-angiogenic therapy using mathematical tools. Proceedings of American Society of Clinical Oncology (ASCO), 21, p. 440a. [PDF]
Skomorovski K, Agur Z. A new method for predicting and optimizing thrombopoietin (TPO) therapeutic protocols in thrombocytopenic patients and in platelet donors. 6 th Annual Meeting Of The European Haematology Association - Frankfurt, Germany, June 2001. [PDF]
Skomorovski K, Vardi M, Harpak H, Wagemaker G. and Agur Z. Using computational approach for optimizing thrombopoietin treatment effects - proof of concept in murine experiments. Proceedings of the 43rd Annual Meeting of the American Society of Hematology, 2001. 4275a. [PDF]
Skomorovski K., Vardi M., Harpak H., Agur Z. Using ‘in silico mouse’ for predicting therapeutic protocols on thrombopoiesis. Eur. Jour. Cancer, Vol. 37 (6), 2001(p.S362). (ECCO 11 - the European Cancer Conference, 21-25 October 2001, Lisbon, Portugal). [PDF]
Arakelyan L, Vainstain V, and Agur Z. Optimizing anti-angiogenic therapy using mathematical tools. Proceedings of American Society of Clinical Oncology (ASCO),2002 21, p. 440a.
Skomorovski K, Vardi M, Harpak H, Wagemaker G and Agur Z. 2001. Using computational approach for optimizing thrombopoietin treatment effects - proof of concept in murine experiments. Proceedings of the 43rd Annual Meeting of the American Society of Hematology,4275a.
Skomorovski K , Vardi M , Harpak H and Agur Z. Using “Virtual Mouse” for Predicting Therapeutic Protocols on Thrombopoiesis. (ECCO 11 - the European Cancer Conference, 21-25 October 2001, Lisbon, Portugal) Eur J Can, 37 (Supp): p S362.
Skomorovski K, Agur Z. A new method for predicting and optimizing thrombopoietin (TPO) therapeutic protocols in thrombocytopenic patients and in platelet donors. 6 th Annual Meeting Of The European Haematology Association - Frankfurt, Germany, June 2001.
Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z, Using Virtual thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham . Hematology Journal. 2003;4(suppl 2):224.
About IMBM |
Scientific Board | IMBM Members |
Research Projects | Applications
Join Us | Press Release |
Events | Publications | HOME